Schaper Benz & Wise Investment Counsel Inc. WI Raises Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Schaper Benz & Wise Investment Counsel Inc. WI increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 44,502 shares of the company’s stock after buying an additional 3,400 shares during the quarter. IDEXX Laboratories comprises about 1.5% of Schaper Benz & Wise Investment Counsel Inc. WI’s investment portfolio, making the stock its 24th biggest position. Schaper Benz & Wise Investment Counsel Inc. WI owned 0.05% of IDEXX Laboratories worth $18,399,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter worth $25,000. Rialto Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth $30,000. Ashton Thomas Securities LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter worth $37,000. Retirement Wealth Solutions LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth $31,000. Finally, Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth $38,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IDXX. Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Stock Performance

IDXX opened at $430.12 on Friday. The business’s 50 day moving average is $437.37 and its 200-day moving average is $449.41. The stock has a market cap of $34.98 billion, a PE ratio of 40.31, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $562.25.

Insider Activity

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.